Genetic addiction risk score (GARS) analysis: Exploratory development of polymorphic risk alleles in poly-drug addicted males

IIOAB Journal

Volumn 1, Issue 2, 2010, Pages 1-14

  Blum, Kenneth ^a,b,f,g   Giordano, John ^b   Morse, Siobhan ^b   Liu, Yiyun ^a   Tan, Jai ^c,d   Bowirrat, Abdalla ^e   Smolen, Andrew ^f   Waite, Roger ^g   Downs, William ^h   Madigan, Margaret ^g   Kerner, Mallory ^h   Fornari, Frank ⁱ   Stice, Eric ^j   Braverman, Eric ^k   Miller, David ^l   Bailey, John ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b G and G Holistic Addiction Treatment Center   (United States)

^c INSTITUTE OF AUTOMATION   (China)

^d XIDIAN UNIVERSITY   (China)

^e ZIV MEDICAL CENTER   (Israel)

^f UNIVERSITY OF COLORADO   (United States)

^g Reward Deficiency Solutions LLC   (United States)

^h Path Foundation   (United States)

ⁱ Dominion Diagnostics   (United States)

^j OREGON RESEARCH INSTITUTE   (United States)

^k WEILL CORNELL MEDICAL COLLEGE   (United States)

^l LifeStream Inc   (United States)

more..

Author keywords

Dopamine; Genetic addiction risk score (GARS); Neurotransmitters; Polymorphic genes; Reward deficiency syndrome (RDS)

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; CATECHOL METHYLTRANSFERASE; DIAMORPHINE; DOPAMINE 2 RECEPTOR; DOPAMINE 4 RECEPTOR; DOPAMINE TRANSPORTER; PSYCHOSTIMULANT AGENT; SEROTONIN TRANSPORTER;

ADULT; ARTICLE; CAUCASIAN; CHINESE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; ETHNICITY; GENE FREQUENCY; GENETIC ADDICTION RISK SCORE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC VARIABILITY; HEROIN DEPENDENCE; HETEROZYGOTE; HUMAN; MALE; MULTIPLE DRUG ABUSE; NEUROTRANSMITTER UPTAKE; PREDICTION; RESIDENTIAL CARE; RISK ASSESSMENT; SCORING SYSTEM;

EID: 79952048968     PISSN: 09763104     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (90)

1. Blum K, Cull JG, Braverman ER, Comings DE. (1996) Reward Deficiency Syndrome. The American Scientist 84: 132-145.
2. Blum K, Braverman ER. (2000) Reward Deficiency Syndrome: A Biogenetic Model For the Diagnosis And Treatment Of Impulsive, Addictive and Compulsive Behaviors. Journal Of Psychoactive Drugs 32: 1-112 (Supplement).
3. Blum K, Sheridan PJ, Wood RC, Braverman ER, et al. (1996) The D2 dopamine receptor gene as a determinant of reward deficiency syndrome. J R Soc Med 89: 396-400.
4. Comings DE, Blum K.(2000) Reward deficiency syndrome: genetic aspects of behavioral disorders. Prog Brain Res 126: 325-41.
5. Di Chiara G, Impereto A.(1988) Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic systems of freely moving rats. Proc Natl Acad Sci U S A 84: 1413-1416.
6. Volkow ND, Fowler JS, Wang GJ.(2002) Role of dopamine in drug reinforcement and addiction in humans: results from imaging studies. Behav Pharmacol 13: 355-366.
7. Eisenberg DT, Campbell B, Mackillop J, Lum JK, Wilson DS.(2007) Season of birth and dopamine receptor gene associations with impulsivity, sensation seeking and reproductive behaviors. PLoS ONE 2:e1216
8. Volkow ND, Chang L, Wang GJ, et al.(2001) Low level of brain dopamine D2 receptors in methamphetamine abusers: Association with metabolism in the orbitofrontal cortex. Am J Psychiat 158: 377-382.
9. Dackis CA, Gold MS, Davies RK, Sweeney DR.(1985).Bromocriptine treatment for cocaine abuse: the dopamine depletion hypothesis. Int J Psychiatry Med 15 (2):125-135.
10. Hietata J, West C, Syvalahti E, et al.(1994) Striatal D2 dopamine receptor binding characteristics in vivo in patients with alcohol dependence. Psychopharmacol 116:285-290.
11. Melis M, Spigra S, & Diana M.(2005) The dopamine hypothesis of drug addiction: Hypodopaminergic State. International Review of Neurobiology 63: 101-154.
12. Rothman RB, Blough BE, Baumann MH.(2007) Dopamine/serotonin releasers as potential medications for stimulant and alcohol addictions. AAPS J 9: E1-10.
13. Boundy VA, Pacheco MA, Guan W, Molinoff PB.(1995) Agonists and antagonists differentially regulate the high affinity state of the D2L receptor in human embryonic kidney 293 cells. Mol Pharmacol 48: 956-964.
14. Thanos PK, Michaelides M, Umegaki H, Volkow ND.(2008) D2R DNA transfer into the nucleus accumbens attenuates cocaine self-administration in rats. Synapse 62: 481-486.
15. Thanos PK, Volkow ND, Freimuth P, Umegaki H, Ikari H, Roth G, Ingram DK, Hitzemann R.(2001) Overexpressionof dopamine D2 receptors reduces alcohol self-administration. J Neurochem 78: 1094-1103.
16. Merlo LJ, Gold MS.(2008) Special Report- Frontiers in psychiatric research: Addiction research: The state of the art in 2008. Psychiatric Times 25: 52-57.
17. Blum K, Noble EP, Sheridan PJ, et al.(1990) Allelic association of human dopamine D2 receptor gene in alcoholism. Journal of the American Medical Association 263: 2055-2060.
18. Neville MJ, Johnstone EC, Walton RT.(2004) Identification and characterization of ANKK1: a novel kinase gene closely linked to DRD2 on chromosome band 11q23.1. Hum Mutat 23: 540-545.
19. Dick DM, Wang JC, Plunkett J, et al.(2007) Family-based association analyses of alcohol dependence phenotypes across DRD2 and neighboring gene ANKK1. Alcohol Clin Exp Res 31: 1645-1653.
20. Huertas E, Ponce G, Koeneke MA, Poch C, España-Serrano L, Palomo T, Jiménez-Arriero MA, Hoenicka J.(2010) The D2 dopamine receptor gene variant C957T affects human fear conditioning and aversive priming. Genes Brain Behav 1: 103-109.
21. Grandy DK, Litt M, Allen L, Bunzow JR, Marchionni M, Makam H, Reed L, Magenis RE, Civelli O.(1989) The human dopamine D2 receptor gene is located on chromosome 11 at q22-q23 and identifies a TaqI RFLP. Am J Hum Genet 45(5): 778-85.
22. Noble EP, Blum K, Ritchie T, Montgomery A, Sheridan P.(1991) Allelic association of the D2 dopamine receptor gene with receptor-binding characteristics. Archives of General Psychiatry 48: 648-654.
23. Pohjalainen T, Rinne JO, Någren K, Lehikoinen P, Anttila K, Syvälahti EK, Hietala J.(1998) The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in healthy volunteers. Mol Psychiatry 3(3): 256-260.
24. Noble EP.(2003) D2 Dopamine receptor gene in psychiatric and neurologic disorders and its phenotypes. Am J Med Genet 116B:103-125.
25. Blum K, Braverman ER, Wood RC, Gill J, Li C, Chen TJ, Taub M, Montgomery AR, Sheridan PJ, Cull JG.(1996) Increased prevalence of the Taq I A1 allele of the dopamine receptor gene (DRD2) in obesity with comorbid substance use disorder: a preliminary report. Pharmacogenetics 6(4): 297-305.
26. Duan J, Wainwright MS, Comeron JM, Saitou N, Sanders AR, Gelernter J, Gejman PV.(2003) Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor. Hum Mol Genet 12: 205-216.
27. Hirvonen M, Laakso A, Någren K, Rinne JO, Pohjalainen T, Hietala J.(2004) C957T polymorphism of the dopamine D2 receptor (DRD2) gene affects striatal DRD2 availability in vivo. Mol Psychiatry 91060-1.
28. Hill SY, Hoffman EK, Zezza N, Thalamuthu A, Weeks DE, Matthews AG, Mukhopadhyay I.(2008) Dopaminergic mutations: within-family association and linkage in multiplex alcohol dependence families. Am J Med Genet B Neuropsychiatr Genet 147B (4):517-26.
29. Berggren U, Fahlke C, Berglund KJ, Wadell K, Zetterberg H, Blennow K, Thelle D, Balldin J.(2010) Dopamine D2 receptor genotype is associated with increased mortality at a 10-year follow-up of alcohol-dependent individuals. Alcohol Alcohol 45:1-5.
30. Kraschewski A, Reese J, Anghelescu I, Winterer G, Schmidt LG, Gallinat J, Finckh U, Rommelspacher H, Wernicke C.(2009) Association of the dopamine D2 receptor gene with alcohol dependence: haplotypes and subgroups of alcoholics as key factors for understanding receptor function. Pharmacogenet Genomics 19: 513-527.
31. Schoots O, Van Tol HH.(2003) The human dopamine D4 receptor repeat sequences modulate expression. Pharmacogenomics J 3: 343-348.
32. Oak JN, Oldenhof J, Van Tol HH.(2000) The dopamine D(4) receptor: one decade of research. Eur J Pharmacol 405: 303-327.
33. McGeary JE, Esposito-Smythers C, Spirito A, Monti PM.(2007) Associations of the dopamine D4 receptor gene VNTR polymorphism with drug use in adolescent psychiatric inpatients. Pharmacol Biochem Behav 86: 401-406.
34. Lusher JM, Chandler C, Ball D.(2001) Dopamine D4 receptor gene (DRD4) is associated with Novelty Seeking (NS) and substance abuse: the saga continues. Mol Psychiatry 6: 497-499.
35. Biederman J, Petty CR, Ten Haagen KS, Small J, Doyle AE, Spencer T, Mick E, Monuteaux MC, Smoller JW, Faraone SV.(2009) Effect of candidate gene polymorphisms on the course of attention deficit hyperactivity disorder. Psychiatry Res 170: 199-203.
36. Grzywacz A, Kucharska-Mazur J, Samochowiec J.(2009) Association studies of dopamine D4 receptor gene exon 3 in patients with alcohol dependence Psychiatr Pol 42: 453-461.
37. Kotler M, Cohen H, Segman R, Gritsenko I, Nemanov L, Lerer B, Kramer I, Zer-Zion M, Kletz I, Ebstein RP.(1997) Excess dopamine D4 receptor (D4DR) exon III seven repeat allele in opioid-dependent subjects.Mol Psychiatry 2: 251-254.
38. Vandenbergh DJ.(1998) Molecular cloning of neurotransmitter transporter genes: beyond coding region of cDNA. Methods Enzymol 296: 498-514.
39. Michelhaugh SK, Fiskerstrand C, Lovejoy E, Bannon MJ, Quinn JP.(2001) The dopamine transporter gene (SLC6A3) variable number of tandem repeats domain enhances transcription in dopamine neurons. J Neurochem 79:1033-8.
40. Guindalini C, Howard M, Haddley K, Laranjeira R, Collier D, Ammar N, Craig I, O'Gara C, Bubb VJ, Greenwood T, Kelsoe J, Asherson P, Murray RM, Castelo A, Quinn JP, Vallada H, Breen G.(2006) A dopamine transporter gene functional variant associated with cocaine abuse in a Brazilian sample. Proc Natl Acad Sci U S A 103: 4552-7.
41. Vandenbergh DJ, Bennett CJ, Grant MD, Strasser AA, O'Connor R, Stauffer RL, Vogler GP, Kozlowski LT.(2002) Smoking status and the human dopamine transporter variable number of tandem repeats (VNTR) polymorphism: failure to replicate and finding that never-smokers may be different. Nicotine Tob Res 4: 333-340.
42. Cook EH Jr, Stein MA, Krasowski MD, Cox NJ, Olkon DM, Kieffer JE, Leventhal BL.(1995) Association of attention-deficit disorder and the dopamine transporter gene. Am J Hum Genet. 56: 993-998.
43. Lee SS, Lahey BB, Waldman I, Van Hulle CA, Rathouz P, Pelham WE, Loney J, Cook EH.(2007) Association of dopamine transporter genotype with disruptive behaviordisorders in an eight-year longitudinal study of children and adolescents. Am J Med Genet B Neuropsychiatr Genet 144B: 310-317.
44. Serý O, Didden W, Mikes V, Pitelová R, Znojil V, Zvolský P.(2006) The association between high-activity COMT allele and alcoholism. Neuro Endocrinol Lett 27: 231-235.
45. Cao L, Li T, Liu X.(2003) Association study of heroin dependence and catechol-O-methyltransferase gene. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 20:127-130.
46. Vandenbergh DJ, Rodriguez LA, Miller IT, Uhl GR, Lachman HM.(1997) High-activity catechol-O-methyltransferase allele is more prevalent in polysubstance abusers. Am J Med Genet 74: 439-442.
47. Wang T, Franke P, Neidt H, Cichon S, Knapp M, Lichtermann D, Maier W, Propping P, Nöthen MM.(2001) Association study of the low-activity allele of catechol-O-methyltransferase and alcoholism using a family-based approach. Mol Psychiatry 6:109-111.
48. Samochowiec J, Kucharska-Mazur J, Grzywacz A, Jabłoński M, Rommelspacher H, Samochowiec A, Sznabowicz M, Horodnicki J, Sagan L, Pełka-Wysiecka J.(2006) Family-based and case-control study of DRD2, DAT, 5HTT, COMT genes polymorphisms in alcohol dependence. Neurosci Lett 410: 1-5.
49. Shih JC.(1991) Molecular basis of human MAO A and B. Neuropsychopharmacology 4: 1-7.
50. Zhu QS, Shih JC.(1997) An extensive repeat structure down-regulates human monoamine oxidase A promoter activity independent of an initiator-like sequence. J Neurochem 69:1368-73.
51. Brummett BH, Krystal AD, Siegler IC, Kuhn C, Surwit RS, Züchner S, Ashley-Koch A, Barefoot JC, Williams RB.(2007) Associations of a regulatory polymorphism of monoamine oxidase-A gene promoter (MAOA-uVNTR) with symptoms of depression and sleep quality. Psychosom Med 69: 396-401.
52. Shih,JC, Chen, K and Ridd MJ (1999) Monoamine Oxidase: From Genes to Behavior. Annu Rev Neurosci. 22: 197-217.
53. Lee SY, Hahn CY, Lee JF, Huang SY, Chen SL, Kuo PH, Lee IH, Yeh TL, Yang YK, Chen SH, Ko HC, Lu RB. (2010) MAOA Interacts With the ALDH2 Gene in Anxiety-Depression Alcohol Dependence. Alcohol Clin Exp Res. (in press)
54. Brummett BH, Boyle SH, Siegler IC, Kuhn CM, Surwit RS, Garrett ME, Collins A, Ashley-Koch A, Williams RB.(2008) HPA axis function in male caregivers: effect of the monoamine oxidase-A gene promoter (MAOA-uVNTR). Biol Psychol 79: 250-255.
55. Lee SY, Hahn CY, Lee JF, Chen SL, Chen SH, Yeh TL, Kuo PH, Lee IH, Yang YK, Huang SY, Ko HC, Lu RB.(2009) MAOA-uVNTR polymorphism may modify the protective effect of ALDH2 gene against alcohol dependence in antisocial personality disorder. Alcohol Clin Exp Res 33: 985-990.
56. Huang SY, Lin WW, Wan FJ, Chang AJ, Ko HC, Wang TJ, Wu PL, Lu RB.(2007) Monoamine oxidase-A polymorphisms might modify the association between the dopamine D2 receptor gene and alcohol dependence. J Psychiatry Neurosci 32:185-192.
57. Vanyukov MM, Maher BS, Devlin B, Tarter RE, Kirillova GP, Yu LM, Ferrell RE.(2004) Haplotypes of the monoamine oxidase genes and the risk for substance use disorders. Am J Med Genet B Neuropsychiatr Genet 125B:120-125.
58. Saiz PA, Garcia-Portilla MP, Florez G, Arango C, Corcoran P, Morales B, Bascaran MT, Alvarez C, San Narciso G, Carreño E, Alvarez V, Coto E, Bobes J.(2009) Differential role of serotonergic polymorphisms in alcohol and heroin dependence. Prog Neuropsychopharmacol Biol Psychiatry 33: 695-700.
59. Seneviratne C, Huang W, Ait-Daoud N, Li MD, Johnson BA.(2009) Characterization of a functional polymorphism in the 3' UTR of SLC6A4 and its association with drinking intensity. Alcohol Clin Exp Res 33: 332-339.
60. Conner BT, Hellemann GS, Ritchie TL, Noble EP.(2010) Genetic, personality, and environmental predictors of drug use in adolescents. J Subst Abuse Trea. 38:178-190.
61. Bossert JM, Ghitza UE, Lu L, Epstein DH, Shaham Y.(2005) Neurobiology of relapse to heroin and cocaine seeking: an update and clinical implications. Eur J Pharmacol 526: 36-50.
62. Li CY, Mao X, Wei L. (2008) Genes and (common) pathways underlying drug addiction. PLoS Comput Biol 2008; 4(1):e2. (http://karg.cbi.pku.edu.cn).
63. Yang BZ, Kranzler HR, Zhao H, Gruen JR, Luo X, Gelernter J.(2008) Haplotypic variants in DRD2, ANKK1, TTC12, and NCAM1 are associated with comorbid alcohol and drug dependence. Alcohol Clin Exp Res 32: 2117-27.
64. Miller D, Bowirrat A, Manka M et al.(2010) Acute Intravenous Synaptamine Complex(KB220) ™ Variant "Normalizes" Neurological Dysregulation in Patients during Protracted Abstinence from Alcohol and Opiates as Observed Using Quantitative Electroencephalographic (qEEG) and Neurotransmitter Genetic Analysis: Two Case Reports. Postgraduate Medicine (in press).
65. Blum K,Chen TJH, Morse S et al.(2010) Overcoming qEEG Abnormalities and Reward Gene Deficits During Protracted Abstinence In Male Psychostimulant and Polydrug Abusers Utilizing Putative Dopamine D2 Agonist Therapy. Postgraduate Medicine (in press).
66. Vandenbergh, D. J, Perisco, A. M, Hawkins, A. L, Griffin, C. A, Li X, Jabs, E. W, and Uhl, G. R.(1992) Human dopamine transporter gene (DAT1) maps to chromosome 5p15.3 and displays a VNTR. Genomics 14:1104-1106.
67. Anchordoquy HC, McGeary C, Liu L, Krauter KS and Smolen A.(2003) Genotyping of three candidate genes following whole genome preamplification of DNA collected from buccal cells. Behav Genet 33: 73-78.
68. Van Tol, H.H, Wu, C.M, Guan, H.C, Ohara, K, Bunzow, J.R, Civelli, O, Kennedy, J, Seeman, P, Niznik H.B. and Jovanovic, V.(1992) Multiple dopamine D4 receptor variants in the human population. Nature 358: 149-152.
69. Lerman, C, Caporaso, N, Main, D, Audrain, J, Boyd, N.R, Bowman, E.D. and Shields, P.G. (1998).Depression and self-medication with nicotine: the modifying influence of the dopamine D4 receptor gene. Health Psychol 17: 56-62.
70. Sabol S.Z, Hu, S. and Hamer D.(1998) A functional polymorphism in the monoamine oxidase A gene promoter. Hum Genet 103: 273-279.
71. Caspi A, McClay J, Moffitt TE, Mill J, Martin J, Craig IW, Taylor A, Poulton R.(2002) Role of genotype in the cycle of violence in maltreated children. Science 297: 851-854.
72. Haberstick, B.C, Lessem, J.M, Hopfer, C.J, Smolen, A, Ehringer, M.A, Timberlake, D, and Hewitt, J.K.(2005) MAOA genotype and antisocial behaviors in the presence of childhood and adolescent maltreatment. Am J Hum Genet (Neuropsych. Genet). 135B: 59-64.
73. Heils, A, A. Teufel, S. Petri, G. Stober, P. Riederer, D. Bengel, and K. P. Lesch.(1992) Allelic Variation of the Human Serotonin Transporter Gene Expression. Journal of Neurochemistry 66: 2621-2624.
74. Lesch, K. P, Bengel, D, Heils, A, Sabol, S. Z, Greenberg, B. D, Petri, S, Benjamin, J, Muller, C. R, Hamer, D. H, and Murphy, D. L.(1996) Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 274: 1527-1531.
75. Hu, X, Oroszi, G, Chun, J, Smith, T.L,Goldman, D, and Schuckit, M.A.(2005) An expanded evaluation of the relationship of four alleles to the level of response to alcohol and the alcoholism risk Alcoholism: Clinical and Experimental Research 29: 8-16.
76. Don RH, Cox PT, Wainwright BJ, Baker K, Mattick JS.(1991) 'Touchdown' PCR to circumvent spurious priming during gene amplification. Nucleic Acids Res 19: 4008.
77. Pohjalainen T, Rinne JO, Nagren K, Lehikoinen P, Anttila K, Syvälahti EK, Hietala J.(1998) The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in healthy volunteers. Mol Psychiatry 3: 256-260.
78. Haberstick, B.C. and Smolen, A.(2004) Genotyping of three single nucleotide polymorphisms following whole genome preamplification of DNA collected from buccal cells. Behav Genet 34: 541-547.
79. Mannisto PT, Kaakkola S.(1999) Catechol-O-methyltransferase (COMT): Biochemistry, Molecular Biology, Pharmacology, and Clinical Efficacy of the New Selective COMT inhibitors. Pharm Rev 51: 593-628.
80. Akil M, Kolachana BS, Rothmond DA, Hyde TM, Weinberger DR, Kleinman JE.(2003) Catechol-O-methyltransferase genotype and dopamine regulation in the human brain. J Neurosci 23: 2008-2013.
81. Bowirrat A, Oscar-Berman M.(2005) Relationship between dopaminergic neurotransmission, alcoholism, and Reward Deficiency syndrome. Am J Med Genet B Neuropsychiatr Genet 132B(1): 29-37.
82. Giordano J, Blum K.(2010) Probing the Mysteries of Recovery through Nutrigenomic and Holistic Medicine: "Science Meets Recovery" through Seminal Translational Research. Counselor Magazine (in press)
83. Blum K, Chen AL, Chen TJ, Braverman ER, Reinking J, Blum SH, Cassel K, Downs BW, Waite RL, Williams L, Prihoda TJ, Kerner MM, Palomo T, Comings DE, Tung H, Rhoades P, Oscar-Berman M.(2008) Activation instead of blocking mesolimbic dopaminergic reward circuitry is a preferred modality in the long term treatment of reward deficiency syndrome (RDS): a commentary. Theor Biol Med Model 12: 5-24.
84. Kirsch P, Reuter M, Mier D, Lonsdorf T, Stark R, Gallhofer B, Vaitl D, Hennig J.(2006) Imaging gene-substance interactions: the effect of the DRD2 TaqIA polymorphism and the dopamine agonist bromocriptine on the brain activation during the anticipation of reward. Neurosci Lett 405:196-201.
85. Stice E, Yokum S, Bohon C, Marti N, Smolen A.(2010) Reward circuitry responsivity to food predicts future increases in body mass: moderating effects of DRD2 and DRD4. Neuroimage 50: 1618-25.
86. Volkow ND, Wang GJ, Begleiter H, Porjesz B, Fowler JS, Telang F, Wong C, Ma Y, Logan J, Goldstein R, Alexoff D, Thanos PK.(2006) High levels of dopamine D2 receptors in unaffected members of alcoholic families: possible protective factors. Arch Gen Psychiatry 63: 999-1008.
87. de Courten-Myers GM.(1999) The human cerebral cortex: gender differences in structure and function. J Neuropathol Exp Neurol 58: 217-226.
88. Kirisci T, Tarter RE, Vanyuku M, et al.(2006) Application of intern response theory to quantify substance use disorder severity. Addictive behaviors 31: 1035-1049.
89. Blum K, Chen TJH, Bowirrat A et al.(2009) Genes & Happiness. Gene Therapy and Mol. Biol 13: 82-120.
90. Blum K, Kozlowski GP.(1990) Ethanol and neurotransmitter interactions: a cascade model of reward. In: Ollat H, Parvez S, Parvez H. eds. Alchol and Behavior, Uterecht,The Netherlands:VSP Press: 131-149.